Antioxidant treatment and endothelial dysfunction: Is it time for flavonoids?

Recent Patents on Cardiovascular Drug Discovery

Volumn 8, Issue 2, 2013, Pages 81-92

  Papageorgiou, Nikolaos ^a,b   Tousoulis, Dimitris ^a   Katsargyris, Athanasios ^c   Charakida, Marietta ^d   Androulakis, Emmanuel ^a   Siasos, Gerasimos ^a   Tentolouris, Costas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antioxidants; Endothelial dysfunction; Flavonoids; Nitric oxide

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ARGININE DERIVATIVE; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVANOL DERIVATIVE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL; FLUINDOSTATIN; FOLIC ACID; GLUCOSE OXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE DERIVATIVE; LIGNAN; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXYNITRITE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; STILBENE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; XANTHINE OXIDASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; APPLE; ARTICLE; BERRY; BIOAVAILABILITY; BROCCOLI; CACAO; CARDIOVASCULAR RISK; CELERY; CHERRY; DIETARY INTAKE; ELECTRON TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLYCOSYLATION; GRAPE; GRAPEFRUIT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; KALE; LEEK; LEGUME; LEMON; MOLECULAR MECHANICS; NONHUMAN; ONION; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RED WINE; SMOKING; SOYBEAN; SPICE; TOMATO; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; VASCULAR DISEASES;

EID: 84888247569     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748901113089990018     Document Type: Article

References (157)

1. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, et al. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 2004; 24: 1614-20.
2. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115: 1285-95.
3. Tousoulis D, Briasoulis A, Papageorgiou N, Tsioufis C, Tsiamis E, Toutouzas K, et al. Oxidative stress and endothelial function: Therapeutic interventions. Rec Pat Cardiovasc Drug Discov 2011; 6: 103-14.
4. Papageorgiou N, Tousoulis D, Androulakis E, Giotakis A, Siasos G, Latsios G, et al. Lifestyle factors and endothelial function. Curr Vasc Pharmacol 2012; 10: 94-106.
5. Tousoulis D, Papageorgiou N, Antoniades C, Giolis A, Bouras G, Gounari P, et al. Acute effects of different types of oil consumption on endothelial function, oxidative stress status and vascular inflammation in healthy volunteers. Br J Nutr 2010; 103: 43-9.
6. Papageorgiou N, Tousoulis D, Psaltopoulou T, Giolis A, Antoniades C, Tsiamis E, et al. Divergent anti-inflammatory effects of different oil acute consumption on healthy individuals. Eur J Clin Nutr 2011; 65: 514-9.
7. Papageorgiou N, Tousoulis D, Stefanadis C. Letter by Papageorgiou, et al regarding article, "OMEGA, a randomized, placebocontrolled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction". Circulation 2011; 124: e22; author reply e24-5.
8. Siasos G, Tsigkou V, Tousoulis D, Kokkou E, Oikonomou E, Vavuranakis M, et al. Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action. Curr Med Chem 2013 [Epub ahead of print]
9. Le Brocq M, Leslie SJ, Milliken P, Megson IL. Endothelial dysfunction: From molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal 2008; 9: 1631-74.
10. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2009; 40: 180-96.
11. Martin BJ, Anderson TJ. Risk prediction in cardiovascular disease: The prognostic significance of endothelial dysfunction. Can J Cardiol 2009; 25: 15A-20A.
12. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-65.
13. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87: 840-4.
14. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004-13.
15. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: Pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125-38.
16. Channon KM. Tetrahydrobiopterin: Regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med 2004; 14: 323-7.
17. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-62.
18. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004; 109: II27-33.
19. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-E41.
20. Stoes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-6.
21. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003; 17: 2328-30.
22. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108: 2000-6.
23. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: Effects of Larginine and B vitamins. Cardiovasc Res 2003; 57: 244-52.
24. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
25. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ Res 2005; 97: e53-e59.
26. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
27. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-66.
28. Hänze J, Weissmann N, Grimminger F, Seeger W, Rose F. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 2007; 97: 774-87.
29. Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem 2007; 282: 18307-17.
30. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007; 93: 1001-7.
31. Haendeler J, Tischler V, Hoffmann J, Zeiher AM, Dimmeler S. Low doses of reactive oxygen species protect endothelial cells from apoptosis by increasing thioredoxin-1 expression. FEBS Lett 2004; 577: 427-33.
32. Irani K. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87: 179-83.
33. Haendeler J, Popp R, Goy C, Tischler V, Zeiher AM, Dimmeler S. Cathepsin D and H2O2 stimulate degradation of thioredoxin-1: Implication for endothelial cell apoptosis. J Biol Chem 2005; 280: 42945-51.
34. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011; 107: 1010-1018. e1.
35. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 740-7.
36. Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med 2005; 22: 1670-6.
37. Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 2010; 126: e225-31.
38. Tousoulis D, Koniari K, Antoniades C, Miliou A, Noutsou M, Nikolopoulou A, et al. Impact of 6 weeks of treatment with lowdose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study. Clin Ther 2010; 32: 1720-8.
39. Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, Sanguigni V, et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J 2008; 29: 54-62.
40. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002; 91: 173-179.
41. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2010; 30: 360-7.
42. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
43. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-modulation by statins. Endothelium 2003; 10: 23-33.
44. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interaction of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39-45.
45. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
46. Inoue T, Takayanagi K, Hayashi T, Morooka S. Fluvastatin attenuate nitrate tolerance in patients with ischemic heart disease. Int J Cardiol 2003; 90: 181-8.
47. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 2002; 105: 393-6.
48. Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, et al. Effect of sulfhydryl and non-sulfhydryl angiotensinconverting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 443-50.
49. Cominacini L, Pasini A, Garbin U, Evangelista S, Crea AE, Tagliacozzi D, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
50. Liu X, Engelman RM, Rousou JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6: 437-43.
51. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169-75.
52. Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: Evidence of an oxidant-sensitive pathway. Mediators Inflamm 2008; 2008: 305087.
53. Wago T, Yoshimoto T, Akaza I, Tsuchiya K, Izumiyama H, Doi M, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res 2010; 33: 796-801.
54. Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hürlimann D, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25: 785-91.
55. Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19: 429-37.
56. Münzel T, Gori T. Nebivolol: the somewhat-different betaadrenergic receptor blocker. J Am Coll Cardiol 2009; 54: 1491-9.
57. Merchant N, Searles CD, Pandian A, Rahman ST, Ferdinand KC, Umpierrez GE, et al. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. J Clin Hypertens (Greenwich) 2009; 11: 720-5.
58. Cominacini L, Fratta Pasini A, Garbin U, Nava C, Davoli A, Criscuoli M, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003; 42: 1838-184.
59. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005; 112: 3795-801.
60. Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007; 55: 303-9.
61. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol prevents NADPH oxidase mediated superoxide formation and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006; 48: 677-684.
62. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: Implications for cardiovascular disease. Hypertension 2004; 43:297-305.
63. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor g ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-7.
64. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005; 288: C899-C905.
65. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.
66. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-201.
67. Antoniades, C., Shirodaria, C., Channon, K.M., Moser, R. Use of folates for the prevention and treatment of vascular diseases. US2010064702 (2010).
68. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
69. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
70. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
71. Briasoulis A, Tousoulis D, Androulakis ES, Papageorgiou N, Latsios G, Stefanadis C. Endothelial dysfunction and atherosclerosis: Focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Discov 2012; 7: 21-32.
72. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res 2000; 87: 349-54.
73. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. J Am Coll Nutr 2003; 22: 18-35.
74. Saremi A, Arora R. Vitamin E and cardiovascular disease. Am J Ther 2010; 17: e56-65.
75. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-55.
76. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
77. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005; 7: 1126-32.
78. Fisher ND, Hurwitz S, Hollenberg NK. Habitual flavonoid intake and endothelial function in healthy humans. J Am Coll Nutr 2012; 31: 275-9.
79. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2009; 2: 270-8.
80. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47.
81. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, Ferri C. Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des 2009; 15: 1072-84.
82. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 2005; 45: 287-306.
83. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr 2005 Jan; 81: 215S-217S.
84. Chen YT, Zheng RL, Jia ZJ, Ju Y. Flavonoids as superoxide scavengers and antioxidants. Free Radic Biol Med 1990; 9: 19-21.
85. Russo A, Acquaviva R, Campisi A, Sorrenti V, Di Giacomo C, Virgata G, et al. Bioflavonoids as antiradicals, antioxidants and DNA cleavage protectors. Cell Biol Toxicol 2000; 16: 91-8.
86. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52: 673-751.
87. Giugliano D. Dietary antioxidants for cardiovascular prevention. Nutr Metab Cardiovasc Dis 2000; 10: 38-44.
88. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997; 37: 693-704.
89. Dufresne CJ, Farnworth ER. A review of latest research findings on the health promotion properties of tea. J Nutr Biochem 2001; 12: 404-21.
90. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 43: 89-143.
91. Mukhtar H, Ahmad N. Tea polyphenols: Prevention of cancer and optimizing health. Am J Clin Nutr 2000; 71: 1698S-702S.
92. Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci 2007; 81: 519-33.
93. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids Free Radic Biol Med 1996; 20: 933-56.
94. Beecher GR. Overview of dietary flavonoids: Nomenclature, occurrence and intake. J Nutr 2003; 133: 3248S-3254S.
95. Williamson G, Clifford MN. Colonic metabolites of berry polyphenols: the missing link to biological activity? Br J Nutr 2010;104: S48-66.
96. Riso P, Klimis-Zacas D, Del Bo' C, Martini D, Campolo J, Vendrame S. Effect of a wild blueberry (Vaccinium angustifolium) drink intervention on markers of oxidative stress, inflammation and endothelial function in humans with cardiovascular risk factors. Eur J Nutr 2013; 52: 949-61.
97. Tousoulis D, Ntarladimas I, Antoniades C, Vasiliadou C, Tentolouris C, Papageorgiou N, et al. Acute effects of different alcoholic beverages on vascular endothelium, inflammatory markers and thrombosis fibrinolysis system. Clin Nutr 2008; 27: 594-600.
98. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
99. Plumb GW, De Pascual-Teresa S, Santos-Buelga C, Cheynier V, Williamson G. Antioxidant properties of catechins and proanthocyanidins: Effect of polymerisation, galloylation and glycosylation. Free Radic Res 1998; 29: 351-8.
100. Reinli K, Block G. Phytoestrogen content of foods--a compendium of literature values. Nutr Cancer 1996; 26: 123-48.
101. Murapa P, Dai J, Chung M, Mumper RJ, D'Orazio J. Anthocyaninrich fractions of blackberry extracts reduce UV-induced free radicals and oxidative damage in keratinocytes. Phytother Res 2012; 26: 106-12.
102. Hertog MG, Hollman PC, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993; 20: 21-9.
103. Okawa M, Kinjo J, Nohara T, Ono M. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. Biol Pharm Bull 2001; 24: 1202-5.
104. Firuzi O, Mladenka P, Petrucci R, Marrosu G, Saso L. Hypochlorite scavenging activity of flavonoids. J Pharm Pharmacol 2004; 56: 801-7.
105. Shiba Y, Kinoshita T, Chuman H, Taketani Y, Takeda E, Kato Y, et al. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites. Chem Res Toxicol 2008; 21: 1600-9.
106. Chang WT, Shao ZH, Yin JJ, Mehendale S, Wang CZ, Qin Y, et al. Comparative effects of flavonoids on oxidant scavenging and ischemia-reperfusion injury in cardiomyocytes. Eur J Pharmacol 2007; 566: 58-66.
107. Sestili P, Diamantini G, Bedini A, Cerioni L, Tommasini I, Tarzia G, et al. Plant-derived phenolic compounds prevent the DNA single-strand breakage and cytotoxicity induced by tertbutylhydroperoxide via an iron-chelating mechanism. Biochem J 2002: 364; 121-8.
108. Steffen Y, Schewe T, Sies H. (-)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase. Biochem Biophys Res Commun 2000; 359: 828-33.
109. Park YC, Rimbach G, Saliou C, Valacchi G, Packer L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett 2000; 465: 93-7.
110. Cos P, Ying L, Calomme M, Hu JP, Cimanga K, Van Poel B, et al. Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. J Nat Prod 1998; 61: 71-6.
111. Costantino L, Rastelli G, Albasini A. Anthocyanidines as inhibitors of xanthine oxidase. Pharmazie 1995; 50: 573-4.
112. Ozyurek M, Bektasoglu B, Guclu K, Apak R. Measurement of xanthine oxidase inhibition activity of phenolics and flavonoids with a modified cupric reducing antioxidant capacity (CUPRAC) method. Anal Chim Acta 2009; 636: 42-50.
113. Steffen Y, Gruber C, Schewe T, Sies H. Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 2008; 469: 209-19.
114. Fuhrman B, Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 2001; 12: 41-8.
115. Nigdikar SV, Williams NR, Griffin BA, Howard AN. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr 1998; 68: 258-65.
116. Mackenzie GG, Carrasquedo F, Delfino JM, Keen CL, Fraga CG, Oteiza PI. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappaB activation at multiple steps in Jurkat T cells. FASEB J 2004; 18: 167-9.
117. Erlejman AG, Jaggers G, Fraga CG, Oteiza PI. TNFalpha-induced NF-kappaB activation and cell oxidant production are modulated by hexameric procyanidins in Caco-2 cells. Arch Biochem Biophys 2008; 476: 186-95.
118. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24.
119. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 2005; 294: 2455-64.
120. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER, 3rd, Lin PH, et al. Effects on blood lipids of a blood pressure-lowering diet: The Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001; 74: 80-9.
121. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular disease. Curr Atheroscler Rep 2003; 5: 492-9.
122. Hung HC, Joshipura KJ, Jiang R, Hu FB, Hunter D, Smith-Warner SA, et al. Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 2004; 96: 1577-84.
123. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002; 105: 2836-44.
124. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001; 154: 495-503.
125. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114: 82-96.
126. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-6.
127. Hertog MG, Feskens EJ, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet 1997; 349: 699.
128. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, et al. Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. Am J Clin Nutr 2007; 85: 895-909.
129. Buijsse B, Feskens EJ, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: The Zutphen Elderly Study. Arch Intern Med 2006; 166: 411-417.
130. Gorelik S, Lapidot T, Shaham I, Granit R, Ligumsky M, Kohen R, et al. Lipid peroxidation and coupled vitamin oxidation in simulated and human gastric fluid inhibited by dietary polyphenols: Health implications. J Agric Food Chem 2005; 53: 3397-402.
131. Schewe T, Steffen Y, Sies H. How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys 2008; 476: 102-6
132. Heiss C, Keen CL, Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J 2010; 31: 2583-92
133. Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (-)-epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways. Hypertension 2010; 55: 1398-405
134. Benito S, Lopez D, Sáiz MP, Buxaderas S, Sánchez J, Puig-Parellada P, et al. A flavonoid-rich diet increases nitric oxide production in rat aorta. Br J Pharmacol 2002; 135: 910-6.
135. Actis-Goretta L, Ottaviani JI, Keen CL, Fraga CG. Inhibition of angiotensin converting enzyme (ACE) activity by flavan-3-ols and procyanidins. FEBS Lett 2003; 555: 597-600.
136. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 2007; 191: 265-71.
137. Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, Cruz M, Rivas M, Cortez-Gomez B, et al. Short-and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2008; 295: H761-7.
138. Steffen Y, Schewe T, Sies H. Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase. Biochem Biophys Res Commun 2005; 331: 1277-83
139. Na HK, Surh YJ. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol 2008; 46: 1271-8
140. Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011; 44: 192-201
141. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005; 81: 317S-25S
142. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012; 95: 454-64.
143. Li H, Xia N, Brausch I, Yao Y, Förstermann U. Flavonoids from artichoke (Cynara scolymus L.) up-regulate endothelial-type nitricoxide synthase gene expression in human endothelial cells. J Pharmacol Exp Ther 2004; 310: 926-32.
144. Andriantsitohaina R, Auger C, Chataigneau T, Étienne-Selloum N, Li H, Martínez MC, et al. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr 2012; 108: 1532-49.
145. Hollman PC, Cassidy A, Comte B, Heinonen M, Richelle M, Richling E, et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr 2011; 141: 989S-1009S.
146. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88: 38-50.
147. Widlansky ME, Gokce N, Keaney JF, Jr., Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-60.
148. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA 2006; 103: 1024-9.
149. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 2008; 88: 1018-25.
150. Widlansky ME, Hamburg NM, Anter E, Holbrook M, Kahn DF, Elliott JG, et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007; 26: 95-102.
151. Flammer AJ, Hermann F, Sudano I, Spieker L, Hermann M, Cooper KA, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007; 116: 2376-82.
152. Rabelink, T., Moser, R. Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (BH4) or derivatives thereof used for the treating or preventing cardiovascular or neurological disorders by modulation of the activity of nitric oxide synthase (NOS). US20030216400 (2003).
153. Murphy, M.P., Smith, R. Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants. US20060229278 (2006).
154. Holland, J., Johnson D. Use of NADPH oxidase inhibitors for a manufacture of medicament for prevention of atherosclerosis. WO1997019679 (1997).
155. Meng, C., Sikorksi, J. Phenolic antioxidants for the treatment of disorders including arthritis, asthma, and coronary artery disease. WO2005112914 (2006).
156. Berk, B.C. Thioredoxin interacting protein (TXNIP) as regulator of vascular function. WO2006078853 (2006).
157. Lockwood, S.F. Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status. WO2007067957 (2007).